Compare Banco Bilbao Vizcaya Argentaria SA (BBVA) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Banco Bilbao Vizcaya Argentaria SA vs Sana Biotechnology Inc — how do they compare? Banco Bilbao Vizcaya Argentaria SA trades at $25.54 (market cap $142.30B), while Sana Biotechnology Inc trades at $3.58 (market cap $994.89M). The key difference: Banco Bilbao Vizcaya Argentaria SA is far larger — about 143× Sana Biotechnology Inc's market cap, and Banco Bilbao Vizcaya Argentaria SA pays a 4.2% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| BBVA | SANA | |
|---|---|---|
Market Cap | $142.30B | $994.89M |
Sector | Financials | Health |
52-Week High | $26.14 | $5.92 |
52-Week Low | $14.73 | $2.68 |
Dividend Yield | 4.2% | — |
Enterprise Value | — | $969.08M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BBVA trades at $25.39, down 1.17% on the day, with a bullish technical signal from moving averages and strong fundamental metrics including a 26.51% net income margin and 18.67% ROE. Recent earnings beat expectations in Q1 2026, and revenue has grown steadily from $28.2B in 2022 to $39.4B in 2025. Positive analyst sentiment is reflected in a 53.85% buy rating, though legal and regulatory risks from ongoing probes in Spain present headwinds.
The outlook for BBVA remains positive given robust profitability and analyst support, but investors should weigh the stock's attractive valuation against litigation risks and sector volatility. Upside potential exists if earnings continue to exceed forecasts, but legal developments could pressure the share price near-term.
SANA Biotechnology trades at $3.64, down 5.45% over 24 hours, with a bullish technical signal and strong analyst support (81.82% buy ratings). Recent news highlights clinical progress, including NEJM publications and conference presentations, but financials show significant losses with a net income of -$244.17M in 2025 and negative cash flows.
The outlook is mixed: strong scientific momentum and Wall Street optimism contrast with deep financial losses and high burn rate. Key risks include funding needs and clinical trial outcomes, while potential upside hinges on successful product development and partnerships.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Banco Bilbao Vizcaya Argentaria SA
Despite its Spanish origins, BBVA generates three quarters of its profits in emerging markets, especially Mexico that contributes nearly half of BBVA's net profit. BBVA is overwhelmingly a retail and commercial bank with corporate and investment banking forming a smaller part of the overall business.
Read more on BBVA →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
